

Accepted Manuscript



TBHP/AIBN-mediated synthesis of 2-Amino-thioazoles from active Methylene ketones and thiourea under metal-free conditions

Jiyun Sun, Huaibin Ge, Xiaohua Zhen, Xuechan An, Guangtao Zhang, Daisy Zhang-Negrerie, Yunfei Du, Kang Zhao

PII: S0040-4020(18)30224-2

DOI: [10.1016/j.tet.2018.02.064](https://doi.org/10.1016/j.tet.2018.02.064)

Reference: TET 29335

To appear in: *Tetrahedron*

Received Date: 4 January 2018

Revised Date: 23 February 2018

Accepted Date: 27 February 2018


Please cite this article as: Sun J, Ge H, Zhen X, An X, Zhang G, Zhang-Negrerie D, Du Y, Zhao K, TBHP/AIBN-mediated synthesis of 2-Amino-thioazoles from active Methylene ketones and thiourea under metal-free conditions, *Tetrahedron* (2018), doi: 10.1016/j.tet.2018.02.064.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Graphical Abstract

TBHP/AIBN-Mediated Synthesis of 2-Amino-thioazoles from Active Methylene Ketones and Thiourea under Metal-free Conditions

Leave this area blank for abstract info.

Jiyun Sun,^a Huaibin Ge,^a Xiaohua Zhen,^a Xuechan An,^a Guangtao Zhang,^a Daisy Zhang-Negrerie,^a Yunfei Du^{a, b, *} and Kang Zhao^{a, *}^aTianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.^bCollaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300072, China.



TBHP/AIBN-Mediated Synthesis of 2-Amino-thioazoles from Active Methylene Ketones and Thiourea under Metal-free Conditions

Jiyun Sun,^a Huaibin Ge,^a Xiaohua Zhen,^a Xuechan An,^a Guangtao Zhang,^a Daisy Zhang-Negrerie,^a Yunfei Du^{a, b, *} and Kang Zhao^{a, *}

^a Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.

^b Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300072, China

ARTICLE INFO

Article history:

Received

Received in revised form

Accepted

Available online

Keywords:

TBHP/AIBN

Metal-free

Active methylene ketone

2-Aminothioazoles

Radical pathway

ABSTRACT


A new oxidative system of *tert*-butyl hydroperoxide (TBHP)/azodiisobutyronitrile (AIBN) has been used for the first time for a convenient, metal-free synthesis of substituted 2-aminothioazoles from active methylene ketone derivatives and thiourea. The reaction is postulated to proceed via an oxidative cyclization initiated by a radical process and followed by a condensation reaction.

2014 Elsevier Ltd. All rights reserved.


1. Introduction

2-Aminothioazole derivatives are known to have promising anti-HIV, antidiabetic, antibacterial, anti-oxidant, anti-inflammatory, antihypertensive, neuroprotective, anticancer, antifungal, and antitubercular activities.¹ Several popular drugs containing the 2-aminothioazole moiety in their chemical structure have proven to be effective for treating multiple diseases.²⁻⁵ For examples, nitazoxanide (Scheme 1, **A**), known as a potent antiprotozoal agent, has entered clinical trials for the hepatitis B and C therapy.² Pramipexole dihydrochloride hydrate (Scheme 1, **B**) has been approved for treatment of Parkinsonism.³ Among many other approved drugs, e.g., riluzole⁴ (voltage-gated sodium channel blockers and glutamate release inhibitor, Scheme 1, **C**) and meloxicam⁵ (antimalum, Scheme 1, **D**), all bear the 2-aminothioazole skeleton in their structures.

Scheme 1. Drug Molecules Containing the 2-Aminothioazole Moiety.




Scheme 2. The Synthetic Routes to Form 2-Aminothioazoles.



Owing to the fact that 2-aminothioazoles represent a privileged scaffold in medicinal chemistry, several strategies targeting the syntheses of such heterocycles have been developed.⁶⁻⁹ A summary of the most commonly practiced synthetic strategies are listed in Scheme 2. Each approach has its own characteristic features in the preparation of the corresponding 2-aminothioazoles bearing the particular functional groups. The use of thiourea or potassium rhodanate as the sulfur source and a substrate containing a carbonyl group with a leaving group at the α -carbon is the most commonly applied strategy. The general reaction pathway is to allow a prefunctionalized ketone to undergo an intermolecular nucleophilic substitution with the sulfur nucleophile of thiourea or potassium rhodanate, followed

by a dehydration reaction at the formation of the C–S bond and a subsequent intramolecular condensation reaction (Scheme 2, a).^{6,7} Furthermore, the prefunctionalization of ketone and intermolecular nucleophilic substitution with the sulfur nucleophile could occur in one-pot process by treatment with I₂ or NBS, etc.^{6b-e} An alternative method is through the formation of the C–S and C–N bonds from vinyl azides and potassium thiocyanate, catalyzed and promoted by palladium(II) acetate and iron(III) bromide, respectively (Scheme 2, c).⁸ The copper-catalyzed coupling of oxime acetates with isothiocyanates could also afford the 2-aminothiazole skeleton via N–O bond cleavage and C–S/C–N bond formation.⁹ However, strategies targeting the synthesis of 2-aminothiazoles via direct C–H bond functionalization at the α -position of the carbonyl group have not yet been reported.

Table 1. Optimization of Reaction Conditions.^a



Entry	Additive	Solvent	Temp. (°C)	Yield (%) ^c
1	none	CH ₃ CN	reflux	45
2	TBAI	CH ₃ CN	reflux	55
3	BPO	CH ₃ CN	reflux	trace
4	CoCl ₂	CH ₃ CN	reflux	66
5	AIBN	CH ₃ CN	reflux	70
6	AIBN	DCE	reflux	50
7	AIBN	DMF	100	72
8	AIBN	MeOH	reflux	83 ^d
9	AIBN	MeOH	40	85
10	AIBN	MeOH	rt	87
11	TBAI	MeOH	rt	78
12	BPO	MeOH	rt	75
13	CoCl ₂	MeOH	rt	85


^a Reaction conditions: **1a** (1.0 mmol), **2a** (2.0 mmol), TBHP (3.0 mmol) and additive (0.2 mmol) in solvent (5 mL); stirred for 2 h unless otherwise stated.

^b TBHP (70% in water) was extracted with petroleum ether and was evaporated before use. ^c Isolated yield. ^d Attempts to isolate and characterize the byproducts from the model reaction at reflux temperature were unsuccessful.

As a powerful oxidant, *tert*-butyl hydroperoxide (TBHP) has found extensive applications in various oxidative reactions.¹⁰⁻¹³ In combination with various catalysts such as iodine,¹⁰ *N*-bromobutanamide (NBS),^{11a} *N*-iodobutanamide (NIS),^{11b,c} tetrabutylammonium iodide (TBAI),¹² and metal catalysts (Co,^{13a} Cu,^{13b-e} Fe,^{13f,g} Ti,^{13h} Ru,¹³ⁱ K^{13j,k}), it has been applied to realize C–C, C–N, C–O, C–S, and N–N bond formations. However, to our best knowledge, TBHP has never been used in combination with AIBN as an oxidative system for the construction of 2-aminothiazoles.¹⁴ Herein, we report for the first time an AIBN/TBHP-mediated synthesis of substituted 2-aminothiazoles from thiourea and ketone derivatives via C–S bond formation and dehydration processes (Scheme 2, “*this work*”), in which a leaving group at α -position of the carbonyl ketone is not needed at all.

2. Results and discussion

Table 2. Scope of the TBHP/AIBN-Mediated Reaction.^{a,e}



3a , 2 h, 87% ^{b,c}	3b , 2 h, 92%	3c , 2 h, 81%
3d , 2 h, 81%	3e , 2 h, 50%	3f , 2 h, 95%
3g , ^d 5 h, 59%	3h , 5 h, 52%	3i , 5 h, 66%
3j , 5 h, 68%	3k , 5 h, 72%	3l , 5 h, 45%
3m , 5 h, 72%	3n , 5 h, 78%	3o , 5 h, 62%
3p , 24 h, 50% conv. 80% yield	3q , 24 h, 50% conv. 52% yield	3r , 12 h, 46%

^a General conditions: substrate **1** (1.0 mmol), thiourea **2** (2.0 mmol), TBHP (3.0 mmol), and AIBN (0.2 mmol) in MeOH (5 mL) at rt. Substrate **1** was consumed completely unless otherwise stated. ^b Isolated yield. ^c The electron withdrawing group (EWG) in products **3** is the same as that in substrate **1**. ^d The reactions of **2g-r** were carried out at 65 °C in order for substrate **1** to be consumed completely. ^e The reaction of the *N*-substituted substrates including *N*-Boc thiourea and *N*-phenyl thiourea were also studied. However, no desired product was obtained in either case.


For the investigation of the reaction, 3-oxo-3-phenylpropanenitrile (**1a**) and thiourea (**2a**) were selected as model substrates. Optimization of the reaction conditions were carried out under various additive, solvents, and reaction temperatures. Additive-screening studies showed that the reaction did not need an additive if the oxidant TBHP was present (Table 1, entry 1); however, the yield, in general, improved in the presence of an initiator. Among the four additives of common choices - TBAI (*tetra-n*-butylammonium iodide),¹² CoCl₂,^{13a} AIBN (2,2'-azo bis(isobutyronitrile))¹⁴ and BPO (benzoyl peroxide)¹⁵ - tested, we found that AIBN was the most effective one for the reaction (Table 1, entries 2-5). Under the newly defined oxidant-initiator system consisting of TBHP and 20 mol% of AIBN, reactions were carried out in three different solvents (Table 1, entries 6-8). Relative to CH₃CN, DCE and

DMF, reaction in MeOH gave the highest, satisfactory yield of 83% (Table 1, entry 8). Further studies on the temperature effect indicated that lower temperature slightly favored the reaction through hampering the formation of side products (Table 1, entries 8-10). However, when the temperature was reduced to below room temperature, it took longer time for the substrate to be consumed completely. Furthermore, additive-screening studies at room temperature in MeOH also indicated AIBN was the most appropriate initiator for this transformation (Table 1, entries 11-13). In summary, the optimal reaction conditions were identified as 20 mol% of AIBN (initiator) and 3.0 equiv. of TBHP (oxidant) in 5.0 mL of MeOH (solvent) at room temperature for 2 h.

Under the optimized reaction conditions, the scope of the reaction was studied using a series of ketones (Table 2). Results show that the reaction could tolerate a range of electron-withdrawing groups at the α -position, including CN, CO₂Me, CO₂Et, COMe, and CPh, with the desired 2-aminothioazoles all obtained in satisfactory to high yields. The electronic effect of the substituent on the phenyl ring in the R group in ketone was shown to be small as the yield values were all rather close among **3a-e** as well as **3g-i** (Table 2). Within the small variances in the yield values, electron-donating groups seemed to favorably affect the reaction while electron-withdrawing groups, negatively. On the other hand, steric effect was evident, as the yield of **3e** was significantly lower than the counterparts of **3a-d**. In addition, other aromatic motifs such as 2-thienyl, 2-pyridyl and 2-naphthyl (Table 2, **3j-l**) adjacent to the carbonyl group, were also successfully tolerated in this process. Notably, for the substrates bearing alkyl groups, the corresponding products were obtained in better yields than those bearing aromatic substituents (Table 2, **3f** compared to **3a-e** and **3m-o** compared to **3g-l**).

Regarding the electron-withdrawing group (EWG) at the α -carbon, the nitrile group gave better yields than all the rest bearing a carbonyl group (**3a-f** compared to **3g-r**). Finally, the method could be applied to 1,3-dione compounds, although the overall yields were, in general, relatively low (Table 2, **3p-r**).


Scheme 3. Proposed Mechanism.



Although the results of the above experimental results are not enough for a convincing mechanism, we postulated a plausible radical mechanistic pathway for this process. As illustrated in Scheme 3, Initially, AIBN, a radical initiator, was converted to radical **I** under heat or stir accompanied by the release of a molecule of N₂.¹⁶ Then the reaction of radical **I** and *tert*-butyl hydroperoxide gave the *tert*-butoxy radical and a molecule of 2-


hydroxy-2-methylpropanenitrile.¹⁷ Hydrogen abstraction of the α -hydrogen of the ketone by the *tert*-butoxy radical produced the carbon radical **III**. Addition reaction across the double bond of C=S in thiourea **2a** by **III** formed radical intermediate **IV**. Then **IV** further reacted with *tert*-butyl hydroperoxide to afford intermediate **V** along with the formation of another *tert*-butoxy radical, which could be used in the next cycle. At the end of the radical process, two dehydration reactions and an isomerization process followed, leading to the title product, 2-aminothioazole.

Scheme 4. Control Studies.



Control experiments were carried out to verify the proposed mechanism (Scheme 4). When 3.0 equiv of TEMPO, an efficient radical scavenger, was added to the reaction mixture under standard conditions, no desired product **3a** was detected (Scheme 4, eq 1). However, methyl 2-oxo-2-phenylacetate **4** was isolated in 81% yield. The result supported a radical process in the reaction sequence. However, no compound **4** was formed when the reaction was run in the absence of thiourea **2a** (Scheme 4, eq 3). When thiourea **2a** was replaced with 1.5 equiv of Et₃N (Scheme 4, eq 2), compound **4** could be obtained in 45% yield. This result indicated that the formation of compound **4** required the involvement of a base, which, we propose here the role of thiourea **2a** in the formation of **4** as described in Scheme 4, eq 1. Furthermore, no condensation reaction occurred when **1a** reacted with **2a** in the absence of TBHP and AIBN. This result implied that the radical reaction occurred prior to the dehydration condensation reaction.

Scheme 5. A Probable Process for the Generation of 4.



Scheme 5 describes the proposed pathway for the formation of **4**. The reaction sequence starts from the cross-coupling of the radical intermediate **III** and TEMPO leading to the formation of intermediate **VII**.¹⁸ With a β -hydrogen elimination under basic conditions, **VII** was converted to 2-oxo-2-phenylacetyl cyanide **VIII** after the release of 2,2,6,6-tetramethylpiperidine as a byproduct.¹⁹ In the presence of MeOH, 2-oxo-2-phenylacetyl cyanide **VIII** was finally converted to compound **4** via a known process.²⁰

Conclusion

In conclusion, we have disclosed for the first time a new, effective oxidative system consisting of TBHP and AIBN, which allowed successful synthesis of substituted 2-aminothiazoles from ketone derivatives and thiourea via a novel, metal-free protocol. The mechanism of the reaction involves the oxidative C–S bond formation via a radical process, subsequently the C–N bond formation via an intramolecular condensation reaction. Further investigation on reaction mechanism is in progression in our group.

3. Experimental Section

3.1. General Information

All reactions were carried out at room temperature under air unless otherwise stated. ¹H and ¹³C NMR spectra were recorded on 600 MHz or 400 MHz spectrometer at 25 °C. Chemical shifts values are given in ppm and referred as the internal standard to TMS: 0.00 ppm. The peak patterns are indicated as follows: s, singlet; d, doublet; t, triplet; q, quartet; qui, quintet; m, multiplet and dd, doublet of doublets, brs, broad singlet. The coupling constants J, are reported in Hertz (Hz). High resolution mass spectrometry (HRMS) was obtained on a Q-TOF micro spectrometer. Melting points were determined with a Micromelting Point Apparatus without corrections. Organic solutions were concentrated by rotary evaporation below 40 °C in vacuum. TLC plates were visualized by exposure to ultraviolet light.

Reagents were purchased as reagent grade and were used without further purification except for TBHP (70% in water, extracted with petroleum ether and was evaporated for use). Solvents were dried by CaH₂ before use. All reactions were performed in standard glassware, heated at 70 °C for 3 h before use. Flash column chromatography was performed over silica gel 200-300 mesh and the eluent was a mixture of ethyl acetate (EA) and petroleum ether (PE).

4.2. General Procedure for Preparation of Substrate 1.

Substrates **1m**, **1n** and **1p-r** were purchased as reagent grade and were used without further purification.

Procedure A^{21, 22d-e}: Substrates **1a-f** were prepared adapted from a previously reported procedure. To a suspension of acetonitrile (20 mmol) in THF (80 mL) was added NaH (40 mmol, 60%). After the reaction mixture was stirred at 0 °C for about 1 h, the ester was added dropwise at the same temperature. The mixture was then refluxed until TLC indicated the complete consumption of the ester. The reaction mixture was poured into ice-water (100 mL), acidified with aqueous HCl (3 M) to pH 2~3 and extracted with EA (100 mL \times 3). The combined organic layer was dried over Na₂SO₄ and evaporated under reduced pressure. The desired pure product was obtained by silica gel chromatography using a mixture of EA/PE (v/v = 2/8) as eluent.

Procedure B²²: Substrates **1g-j** and **1l** were prepared adapted from a previously reported procedure with some modifications:

to a solution of ketone (20 mmol) in THF (80 mL) was added methyl dicarbonate (60 mmol) and NaH (40 mmol, 60%). The reaction mixture was refluxed until TLC indicated complete consumption of the ketone. After cooling, the reaction mixture was poured into ice-water (100 mL), acidified with aqueous HCl (3 M) to pH 2~3 and extracted with EA (100 mL \times 3). The combined organic layer was dried over Na₂SO₄ and evaporated under reduced pressure. The desired pure product was obtained by silica gel chromatography using a mixture of EA/PE (v/v = 1/9) as eluent.

Substrate **1k** was prepared adapted from a previously reported procedure.^{22f}

Procedure C²³: Substrate **1o** was prepared adapted from a previously reported procedure: to an ice-cooled solution of Meldrum's acid (10 mmol) and pyridine (2 mL, 25 mmol) in CH₂Cl₂ (20 mL) was added phenylacetyl chloride (10 mmol) dropwise over a span of 0.5 h. After being stirred at 0 °C for 4 h and at room temperature for 1 h, the mixture was diluted with EtOAc, washed with 1 M HCl and then brine, dried and concentrated. The residue was dissolved in MeOH (30 mL) and heated at 90 °C for 2 h. The desired pure product was obtained by silica gel chromatography using a mixture of EA/PE (v/v = 1/19) as eluent.

4.2.1. 3-Oxo-3-phenylpropanenitrile (1a). Following the general procedure A, **1a** was purified by silica gel chromatography (20% EA/PE). Yield: 92%, yellow solid, mp. 79-80 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.93 (d, J = 7.2 Hz, 2H), 7.67 (t, J = 7.2 Hz, 1H), 7.54 (t, J = 7.8 Hz, 2H), 4.12 (s, 2H). ¹³C NMR (150 MHz, CDCl₃) δ 187.3, 134.8, 134.2, 129.2, 128.5, 114.0, 29.5.

4.2.2. 3-(4-Methoxyphenyl)-3-oxopropanenitrile (1b). Following the general procedure A, **1b** was purified by silica gel chromatography (20% EA/PE). Yield: 72%, yellow solid, mp. 119-120 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.90 (d, J = 8.4 Hz, 2H), 6.98 (d, J = 8.4 Hz, 2H), 4.04 (s, 2H), 3.90 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 185.5, 164.8, 131.0, 127.2, 114.4, 114.2, 55.7, 29.1.

4.2.3. 3-(4-Chlorophenyl)-3-oxopropanenitrile (1c). Following the general procedure A, **1c** was purified by silica gel chromatography (20% EA/PE). Yield: 84%, yellow solid, mp. 124-126 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.88 (d, J = 8.5 Hz, 2H), 7.51 (d, J = 8.5 Hz, 2H), 4.08 (s, 2H). ¹³C NMR (150 MHz, CDCl₃) δ 186.1, 141.5, 132.6, 129.9, 129.6, 113.6, 29.5.

4.2.4. 3-(3-Chlorophenyl)-3-oxopropanenitrile (1d). Following the general procedure A, **1d** was purified by silica gel chromatography (20% EA/PE). Yield: 80%, yellow solid, mp. 73-74 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.89 (s, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.49 (t, J = 7.8 Hz, 1H), 4.15 (s, 2H). ¹³C NMR (150 MHz, CDCl₃) δ 186.1, 135.6 (d, J = 4.8 Hz), 134.7, 130.6, 128.5, 126.6, 113.4, 29.6.

4.2.5. 3-Oxo-3-(o-tolyl)propanenitrile (1e). Following the general procedure A, **1e** was purified by silica gel chromatography (20% EA/PE). Yield: 73%, yellow solid, mp. 83-84 °C. ¹H NMR (600 MHz, CDCl₃) δ 7.63 (d, J = 7.8 Hz, 1H), 7.49 (t, J = 7.5 Hz, 1H), 7.33 (t, J = 7.3 Hz, 2H), 4.07 (s, 2H), 2.58 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 189.3, 140.6, 133.8, 133.4, 132.9, 129.3, 126.2, 114.1, 31.5, 21.9.

4.2.6. 4,4-Dimethyl-3-oxopentanenitrile (1f). Following the general procedure A, **1f** was purified by silica gel chromatography (20% EA/PE). Yield: 55%, colorless solid, mp. 67-68 °C. ¹H NMR (600 MHz, CDCl₃) δ 3.64 (s, 2H), 1.21 (s, 9H). ¹³C NMR (150 MHz, CDCl₃) δ 203.0, 114.3, 44.6, 27.6, 26.1.

4.2.7. Methyl 3-oxo-3-phenylpropanoate (1g). Following the general procedure B, **1g** was purified by silica gel chromatography (10% EA/PE). Yield: 95%, yellow oil. ¹H NMR (600 MHz, CDCl₃) δ 12.51 (s, 0.19H), 7.95 (d, J = 7.3 Hz, 2H),

7.78 (d, $J = 8.4$ Hz, 0.41H), 7.60 (t, $J = 7.4$ Hz, 1H), 7.51–7.45(m, 2.25H), 7.42 (t, $J = 7.4$ Hz, 0.42H), 5.68 (s, 0.2H), 4.02 (s, 2H), 3.80 (s, 0.61H), 3.76 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3) δ 192.4, 173.6, 171.5, 168.0, 135.9, 133.9, 133.3, 131.3, 128.9, 128.6, 128.6, 126.1, 87.1, 52.6, 51.5, 45.7.

4.2.8. Methyl 3-(4-bromophenyl)-3-oxopropanoate (Ih). Following the general procedure B, **1h** was purified by silica gel chromatography (10% EA/PE). Yield: 86%, yellow solid, mp. 45–46 °C. ^1H NMR (600 MHz, CDCl_3) δ 12.49 (s, 0.3H), 7.81 (d, $J = 7.1$ Hz, 2H), 7.63 (d, $J = 6.3$ Hz, 2.6H), 7.55 (d, $J = 7.9$ Hz, 0.63H), 5.66 (s, 0.3H), 3.98 (s, 2H), 3.81 (s, 1H), 3.76 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3) δ 191.4, 173.4, 170.2, 167.7, 134.6, 132.2, 131.8, 130.0, 129.2, 127.6, 125.8, 87.4, 52.7, 51.6, 45.6.

4.2.9. Methyl 3-(4-methoxyphenyl)-3-oxopropanoate (Ii). Following the general procedure B, **1i** was purified by silica gel chromatography (10% EA/PE). Yield: 77%, yellow oil. ^1H NMR (600 MHz, CDCl_3) δ 7.92 (d, $J = 8.8$ Hz, 2H), 6.95 (d, $J = 7.6$ Hz, 2H), 3.97 (s, 2H), 3.87 (s, 3H), 3.75 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3) δ 190.9, 168.2, 164.1, 130.9, 129.0, 127.8, 114.0, 113.9, 85.6, 55.6, 52.5, 51.5, 45.6.

4.2.10. Methyl 3-oxo-3-(thiophen-2-yl)propanoate (Ij). Following the general procedure B, **1j** was purified by silica gel chromatography (10% EA/PE). Yield: 60%, yellow oil. ^1H NMR (600 MHz, CDCl_3) δ 7.75 (d, $J = 3.6$ Hz, 1H), 7.72 (d, $J = 4.8$ Hz, 1H), 7.16 (t, $J = 4.2$ Hz, 1H), 3.95 (s, 2H), 3.76 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3) δ 184.9, 167.5, 143.2, 135.2, 133.4, 128.4, 52.6, 46.2.

4.2.11. Methyl 3-(naphthalen-2-yl)-3-oxopropanoate (Ii). Following the general procedure B, **1i** was purified by silica gel chromatography (10% EA/PE). Yield: 76%, yellow oil. ^1H NMR (600 MHz, CDCl_3) δ 12.61 (s, 0.2H), 8.44 (s, 1H), 8.35 (s, 0.2H), 8.00 (d, $J = 8.6$ Hz, 1H), 7.96 (d, $J = 8.1$ Hz, 1H), 7.88–7.85 (m, 2.6H), 7.64–7.54 (m, 2.6H), 5.82 (s, 0.2H), 4.14 (s, 2H), 3.82 (s, 0.6H), 3.77 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3) δ 192.4, 173.6, 171.3, 168.1, 135.9, 134.7, 132.8, 132.4, 130.7, 130.5, 129.7, 129.0, 128.8, 128.3, 127.9, 127.7, 127.6, 127.0, 126.8, 126.7, 126.5, 123.8, 122.6, 87.8, 52.6, 51.6, 45.8.

4.2.12. Methyl 3-oxo-4-phenylbutanoate (Io). Following the general procedure C, **1o** was purified by silica gel chromatography (10% EA/PE). Yield: 60%, yellow oil. ^1H NMR (600 MHz, CDCl_3) δ 7.35 (t, $J = 7.4$ Hz, 2H), 7.29 (t, $J = 7.4$ Hz, 1H), 7.21 (d, $J = 7.2$ Hz, 2H), 3.83 (s, 2H), 3.71 (s, 3H), 3.47 (s, 2H). ^{13}C NMR (150 MHz, CDCl_3) δ 200.5, 167.6, 133.2, 129.6, 128.9, 127.4, 52.4, 50.1, 48.0.

4.3. General Procedure for Preparation of 2-amino-thiozoles 3.

General procedure: The substrate **1** (1.0 mmol) and thiourea **2** (2.0 mmol) were added to solvent (5 mL methanol) at room temperature. To the reaction mixture, TBHP (3.0 mmol) and AIBN (0.2 mmol) were added respectively. The reaction mixture was stirred at room temperature (for substrates **1a-f**) or reflux temperature (for substrates **1g-r**) until TLC indicated the total consumption of **1** (for substrates **1p-q**, the reaction time is 24 h). The residue was treated with saturated aqueous NaHCO_3 (50 mL) and then extracted with EA (30 mL \times 3). The organic phase was washed with brine (50 mL \times 1), dried over anhydrous Na_2SO_4 . The solvent was removed and the residue was purified by flash column chromatography on silica gel (EA/PE) to afford the desired compound **3**.

4.3.1 2-Amino-4-phenylthiazole-5-carbonitrile (3a). Following the general procedure, **3a** was purified by silica gel chromatography (30% EA/PE). Yield: 87%, white solid, mp. >200 °C. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 8.25 (s, 2H), 7.93 (d, $J = 7.2$ Hz, 2H), 7.56–7.39 (m, 3H). ^{13}C NMR (150 MHz,

$\text{DMSO}-d_6$) δ 170.6, 161.0, 132.5, 130.0, 128.8, 127.4, 115.3, 83.6. HRMS (ESI) calcd for $\text{C}_{10}\text{H}_8\text{N}_3\text{S}^+$ [$\text{M} + \text{H}^+$] 202.0433, found 202.0428.

4.3.2 2-Amino-4-(4-methoxyphenyl)thiazole-5-carbonitrile (3b). Following the general procedure, **3b** was purified by silica gel chromatography (30% EA/PE). Yield: 92%, white solid, mp. 193–194 °C. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 8.19 (s, 2H), 7.90 (d, $J = 9.0$ Hz, 2H), 7.07 (d, $J = 8.4$ Hz, 2H), 3.82 (s, 3H). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$) δ 170.3, 160.8, 160.5, 129.0, 125.1, 115.7, 114.2, 81.8, 55.3. HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{10}\text{N}_3\text{OS}^+$ [$\text{M} + \text{H}^+$] 232.0539, found 232.0533.

4.3.3 2-Amino-4-(4-chlorophenyl)thiazole-5-carbonitrile (3c). Following the general procedure, **3c** was purified by silica gel chromatography (30% EA/PE). Yield: 81%, white solid, mp. >200 °C. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 8.27 (s, 2H), 7.93 (d, $J = 9.0$ Hz, 2H), 7.60 (d, $J = 8.4$ Hz, 2H). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$) δ 170.7, 159.5, 134.6, 131.3, 129.1, 128.9, 115.1, 84.1. HRMS (ESI) calcd for $\text{C}_{10}\text{H}_7\text{ClN}_3\text{S}^+$ [$\text{M} + \text{H}^+$] 236.0044, found 236.0045.

4.3.4 2-Amino-4-(3-chlorophenyl)thiazole-5-carbonitrile (3d). Following the general procedure, **3d** was purified by silica gel chromatography (30% EA/PE). Yield: 81%, white solid, mp. >200 °C. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 8.31 (s, 2H), 7.93 (s, 1H), 7.92–7.85 (m, 1H), 7.56 (d, $J = 4.8$ Hz, 2H). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$) δ 170.7, 158.9, 134.3, 133.5, 130.8, 129.7, 127.1, 125.8, 114.9, 84.7. HRMS (ESI) calcd for $\text{C}_{10}\text{H}_7\text{ClN}_3\text{S}^+$ [$\text{M} + \text{H}^+$] 236.0044, found 236.0049.

4.3.5 2-Amino-4-(o-tolyl)thiazole-5-carbonitrile (3e). Following the general procedure, **3e** was purified by silica gel chromatography (30% EA/PE). Yield: 50%, white solid, mp. >200 °C. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 8.21 (s, 2H), 7.38 (dd, $J = 15.0$, 7.8 Hz, 2H), 7.33 (d, $J = 7.2$ Hz, 1H), 7.28 (t, $J = 7.5$ Hz, 1H), 2.31 (s, 3H). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$) δ 170.8, 163.7, 136.3, 132.6, 130.6, 129.4, 129.3, 125.7, 114.6, 86.5, 19.6. HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{10}\text{N}_3\text{S}^+$ [$\text{M} + \text{H}^+$] 216.0590, found 216.0580.

4.3.6 2-Amino-4-(tert-butyl)thiazole-5-carbonitrile (3f). Following the general procedure, **3f** was purified by silica gel chromatography (30% EA/PE). Yield: 95%, white solid, mp. 188–189 °C. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 7.99 (s, 2H), 1.32 (s, 9H). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$) δ 173.1, 169.8, 115.1, 82.2, 36.4, 29.6. HRMS (ESI) calcd for $\text{C}_8\text{H}_{12}\text{N}_3\text{S}^+$ [$\text{M} + \text{H}^+$] 182.0746, found 182.0737.

4.3.7 Methyl 2-amino-4-phenylthiazole-5-carboxylate (3g). Following the general procedure, **3g** was purified by silica gel chromatography (30% EA/PE). Yield: 59%, white solid, mp. 176–177 °C. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 7.87 (s, 2H), 7.63–7.64 (m, 2H), 7.37–7.38 (m, 3H), 3.62 (s, 3H). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$) δ 169.9, 161.5, 159.0, 134.5, 129.6, 128.7, 127.3, 107.6, 51.3. HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{11}\text{N}_2\text{O}_2\text{S}^+$ [$\text{M} + \text{H}^+$] 235.0536, found 235.0529.

4.3.8 Methyl 2-amino-4-(4-bromophenyl)thiazole-5-carboxylate (3h). Following the general procedure, **3h** was purified by silica gel chromatography (30% EA/PE). Yield: 52%, white solid, mp. >200 °C. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 7.92 (s, 2H), 7.65–7.53 (m, 4H), 3.63 (s, 3H). ^{13}C NMR (151 MHz, $\text{DMSO}-d_6$) δ 167.0, 161.4, 157.6, 133.6, 131.7, 130.4, 122.1, 108.0, 51.5. HRMS (ESI) calcd for $\text{C}_{11}\text{H}_{10}\text{Br}^{79}\text{N}_2\text{O}_2\text{S}^+$ [$\text{M} + \text{H}^+$] 312.9641, found 312.9645.

4.3.9 Methyl 2-amino-4-(4-methoxyphenyl)thiazole-5-carboxylate (3i). Following the general procedure, **3i** was purified by silica gel chromatography (30% EA/PE). Yield: 66%, white solid, mp. 160–161 °C. ^1H NMR (600 MHz, CDCl_3) δ 7.68 (d, $J = 9.0$ Hz, 2H), 6.93 (d, $J = 9.0$ Hz, 2H), 5.91 (s, 2H), 3.84 (s, 3H), 3.74 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 169.0, 162.2, 160.4, 158.8,

131.2, 126.3, 113.1, 109.9, 55.3, 51.8. HRMS (ESI) calcd for $C_{12}H_{13}N_2O_3S^+$ [M + H⁺] 265.0641, found 265.0648.

4.3.10. Methyl 2-amino-4-(thiophen-2-yl)thiazole-5-carboxylate (3j). Following the general procedure, **3j** was purified by silica gel chromatography (30% EA/PE). Yield: 68%, white solid, mp. 172 – 173 °C. ¹H NMR (600 MHz, DMSO-d₆) δ 8.43 – 8.35 (m, 1H), 7.94 (s, 2H), 7.65 (d, J = 4.8 Hz, 1H), 7.14 (dd, J = 4.8, 3.6 Hz, 1H), 3.74 (s, 3H). ¹³C NMR (150 MHz, DMSO-d₆) δ 169.1, 161.6, 151.0, 137.5, 130.1, 129.1, 127.7, 105.4, 51.7. HRMS (ESI) calcd for $C_9H_9N_2O_2S_2^+$ [M + H⁺] 241.0100, found 241.0007.

4.3.11. Methyl 2-amino-4-(pyridin-2-yl)thiazole-5-carboxylate (3k). Following the general procedure, **3k** was purified by silica gel chromatography (30% EA/PE). Yield: 72%, white solid, mp. 180 – 181 °C. ¹H NMR (600 MHz, DMSO-d₆) δ 8.58 (d, J = 4.8 Hz, 1H), 7.88 (s, 2H), 7.83 (td, J = 7.8, 1.5 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.39 (dd, J = 7.2, 5.4 Hz, 1H), 3.59 (s, 3H). ¹³C NMR (150 MHz, DMSO-d₆) δ 170.0, 161.4, 157.6, 153.2, 148.6, 135.9, 124.2, 123.3, 110.0, 51.4. HRMS (ESI) calcd for $C_{10}H_9N_3NaO_2S^+$ [M + Na⁺] 258.0308, found 258.0307.

4.3.12. Methyl 2-amino-4-(naphthalen-2-yl)thiazole-5-carboxylate (3l). Following the general procedure, **3l** was purified by silica gel chromatography (30% EA/PE). Yield: 45%, white solid, mp. 74 – 75 °C. ¹H NMR (600 MHz, DMSO-d₆) δ 8.23 (s, 1H), 7.93 – 7.96 (m, 4H), 7.89 (d, J = 8.4 Hz, 1H), 7.76 (dd, J = 8.4, 1.5 Hz, 1H), 7.53 – 7.56 (m, 2H), 3.64 (s, 3H). ¹³C NMR (150 MHz, DMSO-d₆) δ 169.9, 161.6, 158.9, 132.9, 132.2, 132.0, 129.0, 128.4, 127.4, 126.7, 126.5, 126.2, 107.9, 51.5. Two carbon peaks overlapped. HRMS (ESI) calcd for $C_{15}H_{13}N_2O_2S^+$ [M + H⁺] 285.0692, found 285.0690.

4.3.13. Methyl 2-amino-4-methylthiazole-5-carboxylate (3m). Following the general procedure, **3m** was purified by silica gel chromatography (30% EA/PE). Yield: 72%, white solid, mp. 160 – 161 °C. ¹H NMR (600 MHz, DMSO-d₆) δ 7.74 (s, 2H), 3.67 (s, 3H), 2.38 (s, 3H). ¹³C NMR (150 MHz, DMSO-d₆) δ 170.3, 162.3, 159.6, 106.8, 51.2, 17.1. HRMS (ESI) calcd for $C_6H_9N_2O_2S^+$ [M + H⁺] 173.0379, found 173.0384.

4.3.14. Ethyl 2-amino-4-methylthiazole-5-carboxylate (3n). Following the general procedure, **3n** was purified by silica gel chromatography (30% EA/PE). Yield: 78%, white solid, mp. 170 – 171 °C. ¹H NMR (600 MHz, DMSO-d₆) δ 7.70 (s, 2H), 4.15 (q, J = 7.2 Hz, 2H), 2.38 (s, 3H), 1.23 (t, J = 7.2 Hz, 3H). ¹³C NMR (150 MHz, DMSO-d₆) δ 170.2, 161.9, 159.3, 107.3, 59.7, 17.1, 14.3. HRMS (ESI) calcd for $C_7H_{11}N_2O_2S^+$ [M + H⁺] 187.0536, found 187.0525.

4.3.15. Methyl 2-amino-4-benzylthiazole-5-carboxylate (3o). Following the general procedure, **3o** was purified by silica gel chromatography (30% EA/PE). Yield: 62%, white solid, mp. 199 – 200 °C. ¹H NMR (600 MHz, DMSO-d₆) δ 7.81 (s, 2H), 7.29 – 7.22 (m, 4H), 7.19 – 7.14 (m, 1H), 4.19 (s, 2H), 3.72 (s, 3H). ¹³C NMR (150 MHz, DMSO-d₆) δ 170.6, 162.3, 161.7, 139.1, 128.7, 128.2, 126.0, 107.3, 51.4, 35.6. HRMS (ESI) calcd for $C_{12}H_{13}N_2O_2S^+$ [M + H⁺] 249.0692, found 249.0697.

4.3.16. (2-Amino-4-phenylthiazol-5-yl)(phenyl)methanone (3p). Following the general procedure, **3p** was purified by silica gel chromatography (30% EA/PE). Yield: 80% (50% conv.), white solid, mp. 183 – 184 °C. ¹H NMR (600 MHz, DMSO-d₆) δ 8.06 (s, 2H), 7.40 – 7.33 (m, 2H), 7.32 – 7.26 (m, 1H), 7.23 (d, J = 7.2 Hz, 2H), 7.13 (dd, J = 14.4, 7.2 Hz, 3H), 7.07 (t, J = 7.5 Hz, 2H). ¹³C NMR (150 MHz, DMSO-d₆) δ 187.5, 170.9, 158.9, 138.5, 134.8, 131.1, 129.6, 128.5, 128.3, 127.6, 127.3, 120.5. HRMS (ESI) calcd for $C_{16}H_{13}N_2OS^+$ [M + H⁺] 281.0743, found 281.0741.

4.3.17. 1-(2-Amino-4-methylthiazol-5-yl)ethanone (3q). Following the general procedure, **3q** was purified by silica gel chromatography (30% EA/PE). Yield: 52% (50% conv.), white solid, mp. >200 °C. ¹H NMR (600 MHz, DMSO-d₆) δ 12.02 (s,

1H), 6.72 (s, 1H), 2.25 (s, 3H), 2.11 (s, 3H). ¹³C NMR (150 MHz, DMSO-d₆) δ 168.1, 157.3, 146.5, 107.4, 22.5, 16.9. HRMS (ESI) calcd for $C_6H_9N_2OS^+$ [M + H⁺] 157.0430, found 157.0423.

4.3.18. 1-(2-Amino-4-phenylthiazol-5-yl)ethanone (3r). Following the general procedure, **3r** was purified by silica gel chromatography (30% EA/PE). Yield: 46%, white solid, mp. 138 – 139 °C. ¹H NMR (600 MHz, DMSO-d₆) δ 7.96 (s, 2H), 7.61 (d, J = 7.2 Hz, 2H), 7.56 (t, J = 7.5 Hz, 1H), 7.48 (t, J = 7.5 Hz, 2H), 2.18 (s, 3H). ¹³C NMR (150 MHz, DMSO-d₆) δ 186.6, 171.6, 160.0, 140.9, 131.1, 128.3, 127.5, 118.7, 18.6. HRMS (ESI) calcd for $C_{11}H_{11}N_2OS^+$ [M + H⁺] 219.0587, found 219.0587.

Acknowledgments

We acknowledge the National Natural Science Foundation of China (#21472136), Tianjin Research Program of Application Foundation and Advanced Technology (#15JCZDJC32900) for financial support.

Supplementary Material

Supplementary related to this article can be found at...

Corresponding authors. Tel.: +86-022-27404031; fax: +86-022-27404031.

Email: duyunfeier@tju.edu.cn; kangzhao@tju.edu.cn.

References and notes

- (a) Gouda, M. A.; Berghot, M. A.; Baz, E. A.; Hamama, W. *S. Med. Chem. Res.* 2012, 21, 1062–1070. (b) Iino, T.; Hashimoto, N.; Sasaki, K.; Ohyama, S.; Yoshimoto, R.; Hosaka, H.; Hasegawa, T.; Chiba, M.; Nagata, Y.; Eiki, J.; Nishimura, T. *Bioorg. Med. Chem.* 2009, 17, 3800–3809. (c) Abdel-Wahab, B. F.; Abdel-Aziz, H. A.; Ahmed, E. M. *Eur. J. Med. Chem.* 2009, 44, 2632–2635. (d) Aridoss, G.; Amirthaganesan, S.; Kim, M. S.; Kim, J. T.; Jeong, Y. T. *Eur. J. Med. Chem.* 2009, 44, 4199–4210. (e) Singh, N.; Bhati, S. K.; Kumar, A. *Eur. J. Med. Chem.* 2008, 43, 2597–2609. (f) Adagu, I. S.; Nolder, A.; Warhurst, D. C.; Rossignol, J.-F. *J. Antimicrob. Chemother.* 2002, 49, 103–111. (g) Hines, M. D.; Jones, B. C. Thiazole derivatives to counter advanced glucation, EP1543824A2, Jun 22, 2005.
- Jean-Francois, R.; Raymond, C. 2-Benzamido-5-nitrothiazol-derivate, DE2438037A1, Feb 20, 1975.
- (a) Ferraboschi, P.; Ciceri, S.; Ciuffreda, P.; De Mieri, M.; Romano, D.; Grisenti, P. *Tetrahedron: Asymmetry* 2014, 25, 1239–1245. (b) Schneider, C. S.; Mierau, J. *J. Med. Chem.* 1987, 30, 494–498. (c) Griss, G.; Schneider, C.; Hurnaus, R.; Kobinger, W.; Pichler, L.; Bauer, R.; Mierau, J.; Hinzen, D.; Schingnitz, G. Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals, US4886812A, Dec 12, 1989.
- (a) Jacques, M. Medicament containing 2-amino-6-trifluoro-methoxy benzothiazole, EP0050551A1, Oct 17, 1980. (b) Andrea, F.; Matteo, Z. Process for the preparation of riluzole, EP2284161A1, Sep 21, 2009.
- (a) Gunter, T.; Wolfhard, E. 4-Hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides, processes for their preparation and pharmaceutical compositions containing them, EP0002482B1, Dec 16, 1977. (b) Gunter, T.; Wolfhard, E. 4-Hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides and salts thereof, US4233299A, Dec 16, 1977. (c) Tibor, M.; Gyula, S. Process for preparation of high-purity meloxicam and meloxicam

- potassium salt. WO2006064298A1, Dec 12, **2004**. (d) Liam, M.; Lillian, C. Process for the purification of meloxicam. WO2008062151A1, Nov 20, **2006**. (e) Mezei, T.; Mesterházy, N.; Bakó, T.; Porcs-Makkay, M.; Simig, G.; Volk, B. *Org. Proc. Res. Dev.* **2009**, *13*, 567–572.
6. For selected examples, see: (a) Zhu, Y.-P.; Yuan, J.-J.; Zhao, Q.; Lian, M.; Gao, Q.-H.; Liu, M.-C.; Yang, Y.; Wu, A.-X. *Tetrahedron* **2012**, *68*, 173–178. (b) King, L. C.; Hlavacek, R. J. *J. Am. Chem. Soc.* **1950**, *72*, 3722–3725. (c) Wipf, P.; Aslan, D. C.; Southwick, E. C.; Lazo, J. S. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 313–317. (d) Dahiya, R.; Pujari, H. K. *Indian J. Chem.* **1986**, *25B*, 966. (e) Zarnegar, Z.; Alizadeh, R.; Ahmadzadeh, M.; Safari, J. *J. Mol. Struct.* **2017**, *1144*, 58–65. (f) Desroy, N.; Housseman, C.; Bock, X.; Joncour, A.; Bienvenu, N.; Cherel, L.; Labeguere, V.; Rondet, E.; Peixoto, C.; Grassot, J.-M.; Picolet, O.; Annoot, D.; Triballeau, N.; Monjardet, A.; Wakselman, E.; Roncoroni, V.; Tallec, S. L.; Blaque, R.; Cottreaux, C.; Vandervoort, N.; Christophe, T.; Mollat, P.; Lamers, M.; Auberval, M.; Hrvacic, B.; Ralic, J.; Oste, L.; van der Aar, E.; Brys, R.; Heckmann, B. *J. Med. Chem.* **2017**, *60*, 3580–3590. (g) Lyhen, G. L.; Juan, C. G. New compounds as adenosine A1 receptor antagonists, WO2009044250A1, Apr 09, **2009**. (h) Julio, C.-P. L.; Juan, C. G. Modulators of the adenosine A3 receptors, WO 2016116652A1, Jul 28, **2016**.
 7. Kodomari, M.; Aoyama, T.; Suzuki, Y. *Tetrahedron Lett.* **2002**, *43*, 1717–1720.
 8. Chen, B.; Guo, S.; Guo, X.; Zhang, G.; Yu, Y. *Org. Lett.* **2015**, *17*, 4698–4701.
 9. Tang, X.; Zhu, Z.; Qi, C.; Wu, W.; Jiang, H. *Org. Lett.* **2016**, *18*, 180–183.
 10. (a) Zheng, L.; Zhou, Z.-Z.; He, Y.-T.; Li, L.-H.; Ma, J.-W.; Qiu, Y.-F.; Zhou, P.-X.; Liu, X.-Y.; Xu, P.-F.; Liang, Y.-M. *J. Org. Chem.* **2016**, *81*, 66–76. (b) Volvoikar, P. S.; Tilve, S. G. *Org. Lett.* **2016**, *18*, 892–895. (c) Aruri, H.; Singh, U.; Kumar, S.; Kushwaha, M.; Gupta, A. P.; Vishwakarma, R. A.; Singh, P. P. *Org. Lett.* **2016**, *18*, 3638–3641.
 11. (a) Guntreddi, T.; Vanjari, R.; Singh, K. N. *Tetrahedron*, **2014**, *70*, 3887–3892. (b) Yuan, J.; Liu, C.; Lei, A. *Org. Chem. Front.* **2015**, *2*, 677–680. (c) Lamani, M.; Prabhu, K. R. *Chem. - Eur. J.* **2012**, *18*, 14638–14642.
 12. For selected reviews, see: (a) Liu, D.; Lei, A. *Chem. Asian J.* **2015**, *10*, 806–823. (b) Wu, X.-F.; Gong, J.-L.; Qi, X. *Org. Biomol. Chem.* **2014**, *12*, 5807–5817. (c) Finkbeiner, P.; Nachtsheim, B. J. *Synthesis* **2013**, *45*, 979–999. (d) Uyanik, M.; Ishihara, K. *ChemCatChem.* **2012**, *4*, 177–185. For selected previous works in our lab, see: (e) Sun, J.; Zhang-Negrerie, D.; Du, Y. *Adv. Synth. Catal.* **2016**, *358*, 2035–2040. (f) Dian, L.; Wang, S.; Zhang-Negrerie, D.; Du, Y. *Adv. Synth. Catal.* **2015**, *357*, 3836–3842. (g) Dian, L.; Wang, S.; Zhang-Negrerie, D.; Du, Y.; Zhao, K. *Chem. Commun.* **2014**, *50*, 11738–11741. (h) Yuan, Y.; Hou, W.; Zhang-Negrerie, D.; Zhao, K.; Du, Y. *Org. Lett.* **2014**, *16*, 5410–5413.
 13. For selected examples, see: (a) Yu, J.; Zhang-Negrerie, D.; Du, Y. *Eur. J. Org. Chem.* **2016**, 562–568. (b) Li, Y.-J.; Yan, N.; Liu, C.-H.; Yu, Y.; Zhao, Y.-L. *Org. Lett.* **2017**, *19*, 1160–1163. (c) Hashemi, H.; Saberi, D.; Poorsadeghi, S.; Niknam, Kh. *RSC Adv.* **2017**, *7*, 7619–7622. (d) Yang, Y.; Bao, Y.; Guan, Q.; Sun, Q.; Zha, Z.; Wang, Z. *Green Chem.* **2017**, *19*, 112–116. (e) Hossain, M. M.; Shyu, S.-G. *Tetrahedron*, **2016**, *72*, 4252–4257. (f) Wu, L.-J.; Tan, F.-L.; Li, M.; Song, R.-J.; Li, J.-H. *Org. Chem. Front.* **2017**, *4*, 350–353. (g) Zhang, Y.; Ni, M.; Feng, B. *Org. Biomol. Chem.* **2016**, *14*, 1550–1554. (h) Katsuki, T.; Sharpless, K. B. *J. Am. Chem. Soc.* **1980**, *102*, 5976–5978. (i) Fernandez, X.; Fellous, R.; Duñach, E. *Tetrahedron Lett.* **2000**, *41*, 3381–3384. (j) Kumar, R. A.; Maheswari, C. U.; Ghantasala, S.; Jyothi, C.; Reddy, K. R. *Adv. Synth. Catal.* **2011**, *353*, 401–410. (k) Reddy, K. R.; Maheswari, C. U.; Venkateshwar, M.; Kantam, M. L. *Eur. J. Org. Chem.* **2008**, 3619–3622.
 14. For previously reported applications of TBHP/AIBN as an oxidative system for amidation of various aldehydes with *N*-chloroamines, see: Vanjari, R.; Guntreddi, T.; Singh, K. N. *Green Chem.* **2014**, *16*, 351–356.
 15. Zheng, Z.; Dian, L.; Yuan, Y.; Zhang-Negrerie, D.; Du, Y.; Zhao, K. *J. Org. Chem.* **2014**, *79*, 7451–7458.
 16. (a) Wang, G.-Z.; Li, X.-L.; Dai, J.-J.; Xu, H.-J. *J. Org. Chem.* **2014**, *79*, 7220–7225. (b) Xia, J.; Matyjaszewski, K. *Macromolecules* **1997**, *30*, 7692–7696.
 17. Stannett, V.; Mesrobian, R. *J. Am. Chem. Soc.* **1950**, *72*, 4125–4128.
 18. Wang, Z.-L.; An, X.-L.; Ge, L.-S.; Jin, J.-H.; Luo, X.; Deng, W.-P. *Tetrahedron* **2014**, *70*, 3788–3792.
 19. (a) For the previous formation of this byproduct during a radical pathway, see: Wu, X.-F.; Bheeter, C. B.; Neumann, H.; Dixneuf, P. H.; Beller, M. *Chem. Commun.* **2012**, *48*, 12237–12239. (b) The existence of 2,2,6,6-tetramethylpiperidine in a crude reaction mixture could be confirmed via a MS analysis.
 20. Xie, Y.; Liu, J.; Huang, Y.; Yao, L. *Tetrahedron Lett.* **2015**, *56*, 3793–3795.
 21. Liu, X.; Cheng, R.; Zhao, F.; Zhang-Negrerie, D.; Du, Y.; Zhao, K. *Org. Lett.* **2012**, *14*, 5480–5483.
 22. (a) Eid Jr., C. N.; Konopelski, J. P. *Tetrahedron* **1991**, *47*, 975–992. (b) Yu, W.; Du, Y.; Zhao, K. *Org. Lett.* **2009**, *11*, 2417–2420. (c) Zhao, F.; Liu, X.; Qi, R.; Zhang-Negrerie, D.; Huang, J.; Du, Y.; Zhao, K. *J. Org. Chem.* **2011**, *76*, 10338–10344. (d) Sun, X.; Lyu, Y.; Zhang-Negrerie, D.; Du, Y.; Zhao, K. *Org. Lett.* **2013**, *15*, 6222–6225. (e) Yuan, Y. C.; Hou, W.; Zhang-Negrerie, D.; Zhao, K.; Du, Y. *Org. Lett.* **2014**, *16*, 5410–5413. (f) Yang, H.; Huo, N.; Yang, P.; Pei, H.; Lv, H.; Zhang, X. *Org. Lett.* **2015**, *17*, 4144–4147.
 23. Matsubara, T.; Takahashi, K.; Ishihara, J.; Hatakeyama, S. *Angew. Chem., Int. Ed.* **2014**, *53*, 757–760.